Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.

Xiong A, Yao W, Zheng W, Yu Y, Chen P, Zhong H, Ge J, Wang H, Chen B, Wang H, Fan Y, Yang Y, Pu X, Song X, Wang Q, Du X, Huang Z, Li X, Luo H, Yao Y, Yu Q, Su C, He L, Jiang G, Cui J, Liu C, Yi T, Che G, Liu Z, Zhang L, Zhou M, Fang Y, Wei Y, Qing Y, Jin X, Zhou C

Open source

DOI: 10.1016/s0140-6736(26)00968-2
Published: 2026 Jun 27
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00968-2,
  title = {Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.},
  author = {Xiong A and Yao W and Zheng W and Yu Y and Chen P and Zhong H and Ge J and Wang H and Chen B and Wang H and Fan Y and Yang Y and Pu X and Song X and Wang Q and Du X and Huang Z and Li X and Luo H and Yao Y and Yu Q and Su C and He L and Jiang G and Cui J and Liu C and Yi T and Che G and Liu Z and Zhang L and Zhou M and Fang Y and Wei Y and Qing Y and Jin X and Zhou C},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00968-2},
  url = {https://doi.org/10.1016/s0140-6736(26)00968-2}
}

RIS

TY  - JOUR
TI  - Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
AU  - Xiong A
AU  - Yao W
AU  - Zheng W
AU  - Yu Y
AU  - Chen P
AU  - Zhong H
AU  - Ge J
AU  - Wang H
AU  - Chen B
AU  - Wang H
AU  - Fan Y
AU  - Yang Y
AU  - Pu X
AU  - Song X
AU  - Wang Q
AU  - Du X
AU  - Huang Z
AU  - Li X
AU  - Luo H
AU  - Yao Y
AU  - Yu Q
AU  - Su C
AU  - He L
AU  - Jiang G
AU  - Cui J
AU  - Liu C
AU  - Yi T
AU  - Che G
AU  - Liu Z
AU  - Zhang L
AU  - Zhou M
AU  - Fang Y
AU  - Wei Y
AU  - Qing Y
AU  - Jin X
AU  - Zhou C
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00968-2
UR  - https://doi.org/10.1016/s0140-6736(26)00968-2
ER  -

APA

A, X., W, Y., W, Z., Y, Y., P, C., H, Z., J, G., H, W., B, C., H, W., Y, F., Y, Y., X, P., X, S., Q, W., X, D., Z, H., X, L., H, L., Y, Y., Q, Y., C, S., L, H., G, J., J, C., C, L., T, Y., G, C., Z, L., L, Z., M, Z., Y, F., Y, W., Y, Q., X, J., & C, Z. (2026). Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00968-2

Source records

pubmed · retrieved 2026-09-26T19:45:11.952Z